Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Equity Investor

Julia Lee
May 16, 2018

Market Update

Julia Lee
May 10, 2018

Equity Investor 7 May

Julia Lee
May 8, 2018

Market Update

Julia Lee
April 26, 2018

Market Update

Julia Lee
April 26, 2018

Equity Investor 23 April 2018

Bell Direct
April 24, 2018

Market Update

Julia Lee
April 18, 2018

Equity Investor 16 April

Julia Lee
April 17, 2018

Market Update

Julia Lee
April 12, 2018

LIC video – understand the basics

Bell Direct
April 11, 2018